CTOs on the Move

Centre for Commercialization of Regenerative Med

www.ccrm.ca

 
Centre for Commercialization of Regenerative Medicine , a Canadian not-for-profit organization funded by the Government of Canada`s Networks of Centres of Excellence program, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. CCRM aims to accelerate the translation of scientific discovery into marketable products for patients with specialized teams funding, and infrastructure. CCRM sources and evaluates intellectual property from around the globe, offers various consulting services, conducts development projects with partners, and establishes new companies built around strategic bundles of ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.ccrm.ca
  • The Banting Institute Suite 110-100 College Street
    Toronto, ON CAN M5G 1L5
  • Phone: 416.978.3751

Executives

Name Title Contact Details
Kim Warren
 Chief Technology Officer Profile

Similar Companies

BioXcel

BioXcel is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sports Performance International

Sports Performance International is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

C2N Diagnostics

C2N Diagnostics is a privately-held biotechnology company based in St. Louis, Missouri. We focus on the development of clinical diagnostics and therapeutics for serious brain disorders, with a particular emphasis on Alzheimer`s disease and related forms of progressive neurodegeneration.

Octapharma Plasma

Octapharma Plasma is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Replimune

Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse. Replimune`s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel tumor-directed oncolytic immunotherapies. We imagine a world where cancer is a curable disease.